Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years

EndpointsView source article

Part of story

Biogen's anti-tau Alzheimer's drug shows 38% slowing of decline at two years

New trial data show the lowest dose of Biogen's experimental tau-reducing drug slowed cognitive decline in early Alzheimer's patients by 38% after two years, with benefits increasing over time.

Nov 17, 2026·2 sourcesDrug developmentNeurodegenerative diseaseAlzheimer’s & dementiaClinical trialsEli LillyAlzheimer's diseasePharmaceutical IndustryCognitive decline
Biogen's anti-tau Alzheimer's drug shows 38% slowing of decline at two years
00

Other sources for this story

Reuters

Biogen's anti-tau Alzheimer's drug benefits increase at 2 years | Reuters